Table 3.

Medical targeting of MDSC#

	Drug	Mechanism	Effect on MDSC	Reference
FDA approved drugs*	Bevacizumab		no effect in vivo on human MDSC	[22]
	ATRA	differentiation of MDSC via neutralization of ROS	in vivo on human MDSC	[16, 59].
	Sunitinib	STAT3 and c-kit mediated	in vivo on human MDSC	[48, 60]
	5-FU	Selective killing of MDSC	in vivo on murine MDSC	[61]
	Gemcitabine	apoptosis of MDSC	in vivo on murine MDSC	[42]
	PDE5 inhibitors	downregulates IL4Ra and impairs MDSC function	in vivo on murine MDSC	[62]
	COX2 inhibitors	blocks arginase 1 induction	in vivo on murine MDSC	[63, 64]
	Amino- Bisphosphonate	inhibiting MMP-9 expression	in vivo on murine MDSC	[65]
	Vitamin D3	increases HLA-DR and reduces CD34+ cells	in vivo on murine and human MDSC	[66, 67]
Compounds in clinical development	VEGF-trap		no effect on human MDSC	[68]
	synthetic triterpenoids	ROS blockade	in vivo on murine MDSC	[69]
	NO-releasing aspirin	Inhibits ARG1 and NOS2	in vivo on murine MDSC	[70]

^*FDA approval for different indication than MDSC targeting